The mesentery in Crohn's disease: Friend or foe?

Current Opinion in Gastroenterology

Volumn 32, Issue 4, 2016, Pages 267-273

  Coffey, John Calvin ^a,b,c   O'Leary, Donal Peter ^a   Kiernan, Miranda G ^b,c   Faul, Peter ^a  

^a UNIVERSITY HOSPITAL LIMERICK   (Ireland)

^b UNIVERSITY OF LIMERICK   (Ireland)

^c UNIVERSITY OF LIMERICK   (Ireland)

Author keywords

Crohn's disease; mesentery; mesocolic excision; submucosa

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; IMMUNOSUPPRESSIVE AGENT; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RESISTIN;

ADIPOCYTE; BACTERIAL TRANSLOCATION; CELL DIFFERENTIATION; CELL HYPERPLASIA; COMPUTER ASSISTED TOMOGRAPHY; CONNECTIVE TISSUE; CROHN DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; EXCISION; HISTOLOGY; HUMAN; INTESTINE RESECTION; INTESTINE ULCER; INTRAABDOMINAL FAT; LIVER CIRRHOSIS; MACROPHAGE; MESENTERIC FAT; MESENTERITIS; MESOTHELIUM CELL; METABOLIC SYNDROME X; MICROSCOPY; MUCOSAL DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PATHOLOGY; PROTEIN BLOOD LEVEL; REOPERATION; REVIEW; COLONOSCOPY; MESENTERY; POSTOPERATIVE COMPLICATION; PROCEDURES; RECURRENT DISEASE; RISK FACTOR; SECONDARY PREVENTION;

COLONOSCOPY; CROHN DISEASE; HUMANS; MESENTERY; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RISK FACTORS; SECONDARY PREVENTION;

EID: 84964483994     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000280     Document Type: Review

References (87)

1. Lewis RT, Maron DJ. Efficacy and complications of surgery for Crohn's disease. Gastroenterol Hepatol (NY) 2010; 6:587-596.
2. Chardavoyne R, Flint GW, Pollack S, Wise L. Factors affecting recurrence following resection for Crohn's disease. Dis Col Rect 1986; 29:495-502.
3. Burke JP, Velupillai Y, O'Connell PR, Coffey JC. National trends in intestinal resection for Crohn's disease in the postbiologic era. Int J Colorectal Dis 2013; 28:1401-1406.
4. Pizarro TT, Michie MH, Bentz M, et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol 1999; 162:6829-6835.
5. Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of adherentinvasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004; 127:412-421.
6. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009; 9:313-323.
7. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010; 138:463-468.
8. Strong SA. Surgical management of Crohn's disease. In: Holzheimer RG, Mannick JA, editors. Surgical treatment: evidence-based and problem-oriented. Munich: Zuckschwerdt; 2001.
9. Shaffer VO, Wexner SD. Surgical management of Crohn's disease. Langenbecks Arch Surg 2012; 398:13-27.
10. Borley NR, Mortensen NJ, Jewell DP, Warren BF. The relationship between inflammatory and serosal connective tissue changes in ileal Crohn's disease: evidence for a possible causative link. J Pathol 2000; 190:196-202.
11. Behr MA. The path to Crohn's disease: is mucosal pathology a secondary event? Inflamm Bowel Dis 2010; 16:896-902.
12. Shelley-Fraser G, Borley NR, Warren BF, Shepherd NA. The connective tissue changes of Crohn's disease. Histopathology 2012; 60:1034-1044.
13. Culligan K, Coffey JC, Kiran RP, et al. The mesocolon: a prospective observational study. Colorectal Dis 2012; 14:421-428.
14. Culligan K, Walsh S, Dunne C, et al. The mesocolon: a histological and electron microscopic characterization of the mesenteric attachment of the colon prior to and after surgical mobilization. Ann Surg 2014; 260:1048-1056.
15. Coffey JC, Dillon M, Sehgal R, et al. Mesenteric-based surgery exploits gastrointestinal, peritoneal, mesenteric and fascial continuity from duodenojejunal flexure to the anorectal junction: a review. Dig Surg 2015; 32:291-300.
16. Culligan K, Sehgal R, Mulligan D, et al. A detailed appraisal of mesocolic lymphangiology: an immunohistochemical and stereological analysis. J Anat 2014; 225:463-472.
17. Peyrin-Biroulet L, Chamaillard M, Gonzalez F, et al. Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander? Gut 2007; 56:577-583.
18. Kredel L, Batra A, Siegmund B. Role of fat and adipokines in intestinal inflammation. Curr Opin Gastroenterol 2014; 30:561-565.
19. Souza DG, Guabiraba R, Pinho V, et al. IL-1-driven endogenous IL-10 production protects against the systemic and local acute inflammatory response following intestinal reperfusion injury. J Immunol 2003; 170:4759-4766.
20. Coombes JL, Robinson NJ, Maloy KJ, et al. Regulatory T cells and intestinal homeostasis. Immunol Rev 2005; 204:184-194.
21. Peyrin-Biroulet L, Gonzalez F, Dubuquoy L, et al. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut 2012; 61:78-85.
22. Schaffler A, Scholmerich J, Buchler C. Mechanisms of disease: adipocytokines and visceral adipose tissue-emerging role in intestinal and mesenteric diseases. Nat Clin Pract Gastroenterol Hepatol 2005; 2:103-111.
23. Culligan K, Remzi FH, Soop M, Coffey JC. Review of nomenclature in colonic surgery: proposal of a standardised nomenclature based on mesocolic anatomy. Surgeon 2013; 11:1-5.
24. Mainous MR, Ertel W, Chaudry IH, Deitch EA. The gut: a cytokine-generating organ in systemic inflammation? Shock 1995; 4:193-199.
25. Willoughby L, Dark P, Warhurst G. Investigation of systemic and mesenteric inflammatory signaling and gut-derived endothelial toxicity in patients undergoing high-risk abdominal aortic surgery. Shock 2011; 36:121-127.
26. Wei B, Velazquez P, Turovskaya O, et al. Mesenteric B cells centrally inhibit CD4+ T cell colitis through interaction with regulatory T cell subsets. Proc Natl Acad Sci U S A 2005; 102:2010-2015.
27. Diehl GE, Longman RS, Zhang JX, et al. Microbiota restricts trafficking of bacteria to mesenteric lymph nodes by CX(3)CR1(hi) cells. Nature 2013; 494:116-120.
28. Fruhbeck G. Overview of adipose tissue and its role in obesity and metabolic disorders. Methods Mol Biol 2008; 456:1-22.
29. Fink C, Karagiannides I, Bakirtzi K, Pothoulakis C. Adipose tissue and inflammatory bowel disease pathogenesis. Inflamm Bowel Dis 2012; 18:1550-1557.
30. Sideri A, Bakirtzi K, Shih DQ, et al. Substance P mediates pro-inflammatory cytokine release form mesenteric adipocytes in inflammatory bowel disease patients. Cell Mol Gastroenterol Hepatol 2015; 1:420-432.
31. Le Dréan G, Haure-Mirande V, Ferrier L, et al. Visceral adipose tissue and leptin increase colonic epithelial tight junction permeability via a RhoA-ROCKdependent pathway. FASEB J 2014; 28:1059-1070.
32. Siegmund B. Mesenteric fat in Crohn's disease: the hot spot of inflammation? Gut 2012; 61:3-5.
33. Mutsaers SE, Birnie K, Lansley S, et al. Mesothelial cells in tissue repair and fibrosis. Front Pharmacol 2015; 6:113.
34. Drouet M, Dubuquoy L, Desreumaux P, Bertin B. Visceral fat and gut inflammation. Nutrition 2012; 28:113-117.
35. Pauls S, Kratzer W, Rieber A, et al. Quantifying the inflammatory activity in Crohn's disease using CE dynamic MRI. Rofo 2003; 175:1093-1099.
36. Barbier M, Vidal H, Desreumaux P, et al. Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. Gastroenterol Clin Biol 2003; 27:987-991.
37. Bayless TM, Hanauer SB; IBD and Crohn's disease. Advanced therapy in inflammatory bowel disease. USA: People's Medical Publishing House; 2011.
38. Cameron JL, Hamilton SR, Coleman J, et al. Patterns of ileal recurrence in Crohn's disease. A prospective randomized study. Ann Surg 1992; 215:546-551.
39. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis; a pathologic and clinical entity. Am J Med 1932; 13:583-590.
40. Karagiannides I, Pothoulakis C. Neuropeptides, mesenteric fat, and intestinal inflammation. Ann NY Acad Sci 2008; 1144:127-135.
41. Burke JP, Mulsow JJ, O'Keane C, et al. Fibrogenesis in Crohn's Disease. Am J Gastroenterol 2007; 102:439-448.
42. Burke JP, Cunningham MF, Sweeney C, et al. N-cadherin is overexpressed in Crohn's stricture fibroblasts and promotes intestinal fibroblast migration. Inflamm Bowel Dis 2011; 17:1665-1673.
43. Li C, Kuemmerle JF. The mechanisms that mediate the development of fibrosis in patients with Crohn's Disease. Inflamm Bowel Dis 2014; 20:1250-1258.
44. Wilkinson L, De P, Bloxham C. Mesothelial reaction in longstanding Crohn's ileitis simulating papillary mesothelioma. J Clin Pathol 2008; 61:1119-1121.
45. Zulian A, Cancello R, Micheletto G, et al. Visceral adipocytes: old actors in obesity and new protagonists in Crohn's disease? Gut 2012; 61:86-94.
46. Soucy G, Wang HH, Farraye FA, et al. Clinical and pathological analysis of colonic Crohn's disease, including a subgroup with ulcerative colitis-like features. Mod Pathol 2012; 25:295-307.
47. Sheehan AL, Warren BF, Gear MWL, Shepherd NA. Fat-wrapping in Crohn's disease: pathological basis and relevance to surgical practice. Br J Surg 1992; 79:955-958.
48. Bucala R, Spiegel LA, Chesney J, et al. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1994; 1:71-81.
49. Hong KM, Belperio JA, Keane MP, et al. Differentiation of human circulating fibrocytes as mediated by transforming growth factor-b and peroxisome proliferator-activated receptor g. J Biol Chem 2007; 282:22910-22920.
50. Sazuka S, Katsuno T, Nakagawa T, et al. Fibrocytes are involved in inflammation as well as fibrosis in the pathogenesis of Crohn's disease. Dig Dis Sci 2014; 59:760-768.
51. Sahebally SM, Burke JP, Chang KH, et al. Circulating fibrocytes and Crohn's disease. Brit J Surg 2013; 100:1549-1556.
52. Wang CH, Huang CD, Lin HC, et al. Increased circulating fibrocytes in asthma with chronic airflow obstruction. Am J Respir Crit Care Med 2008; 178:583-591.
53. Moeller A, Gilpin SE, Ask K, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179:588-594.
54. Mathai SK, Gulati M, Peng X, et al. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab Invest 2010; 90:812-823.
55. Brenner DA, Kisseleva T, Scholten D, et al. Origin of myofibroblasts in liver fibrosis. Fibrogenesis Tissue Repair 2012; 5 (Suppl 1):S17.
56. Hinz B, Phan SH, Thannickal VJ, et al. The myofibroblast: one function, multiple origins. Am J Pathol 2007; 170:1807-1816.
57. Rieder F, Kessler SP, West GA, et al. Inflammation-induced endothelial-tomesenchymal transition: a novel mechanism of intestinal fibrosis. Am J Pathol 2011; 179:2660-2673.
58. Kitao A, Sato Y, Sawada-Kitamura S, et al. Endothelial to mesenchymal transition via transforming growth factor-b1/Smad activation is associated with portal venous stenosis in idiopathic portal hypertension. Am J Pathol 2009; 175:616-626.
59. Rodrigues VS, Milanski M, Fagundes JJ, et al. Serum levels and mesenteric fat tissue expression of adiponectin and leptin in patients with Crohn's disease. Clin Exp Immunol 2012; 170:358-364.
60. Batra A, Heimesaat MM, Bereswill S, et al. Mesenteric fat: control site for bacterial translocation in colitis? Muc Immunol 2012; 5:580-591.
61. Forouhi NG, Sattar N, McKeigue PM. Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int J Obes Relat Metab Disord 2001; 25:1327.
62. Amato MC, Magistro A, Gambino G, et al. Visceral adiposity index and DHEAS are useful markers of diabetes risk in women with polycystic ovary syndrome. Eur J Endocrinol 2015; 172:79-88.
63. Yang Y, Feng Y, Ma X, et al. Visceral adiposity index and insulin secretion and action in first-degree relatives of subjects with type 2 diabetes. Diabetes Metab Res Rev 2015; 31:315-321.
64. Finelli C, Sommella L, Gioia S, et al. Should visceral fat be reduced to increase longevity? Ageing Res Rev 2013; 12:996-1004.
65. Amato MC, Giordano C. Visceral adiposity index: an indicator of adipose tissue dysfunction. Int J Endocrinol 2014; 2014:7308-7327.
66. Valentini L, Wirth EK, Schweizer U, et al. Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease. Nutrition 2009; 25:172-181.
67. Yamamoto K, Kiyohara T, Murayama Y, et al. Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease. Gut 2005; 54:789-796.
68. Paul G, Schaffler A, Neumeier M, et al. Profiling adipocytokine secretion from creeping fat in Crohn's disease. Inflamm Bowel Dis 2006; 12:471-477.
69. Karmiris K, Koutroubakis IE, Xidakis C, et al. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12:100-105.
70. Konrad A, Lehrke M, Schachinger V, et al. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol 2007; 19:1070-1074.
71. Mencarelli A, Distrutti E, Renga B, et al. Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. PLoS One 2011; 6:e22978.
72. Clemente TRL, Dos Santos AN, Sturaro JN, et al. Infliximab modifies mesenteric adipose tissue alterations and intestinal inflammation in rats with TNBSinduced colitis. Scan J Gastroenterol 2012; 47:943-950.
73. Siersbaek R, Nielsen R, Mandrup S. PPARgamma in adipocyte differentiation and metabolism-novel insights from genome-wide studies. FEBS Lett 2010; 584:3242-3249.
74. Kredel LI, Batra A, Stroh T, et al. Adipokines from local fat cells shape the macrophage compartment of the creeping fat in Crohn's disease. Gut 2013; 62:852-862.
75. Louis E, Collard A, Oger AF, et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001; 49:777-782.
76. Hoffmann JC, Preiss JC, Autschbach F, et al. Clinical practice guideline on diagnosis and treatment of Crohn's disease. Z Gastroenterol 2008; 46:1094-1146.
77. Desreumaux P, Ernst O, Geboes K, et al. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology 1999; 117:73-81.
78. Mao R, Liao WD, He Y, et al. Computed tomographic enterography adds value to colonoscopy in differentiating Crohn's disease from intestinal tuberculosis: a potential diagnostic algorithm. Endoscopy 2015; 47:322-329.
79. Punwani S, Rodriguez-Justo M, Bainbridge A, et al. Mural inflammation in Crohn disease: location-matched histologic validation of MR imaging features. Radiology 2009; 252:712-720.
80. Cornet A, Savidge TC, Cabarrocas J, et al. Enterocolitis induced by autoimmune targeting of enteric glial cells: a possible mechanism in Crohn's disease? Proc Natl Acad Sci U S A 2001; 98:13306-13311.
81. Brahme F, Lindstrom C. A comparative radiographic and pathological study of intestinal vaso-architecture in Crohn's disease and in ulcerative colitis. Gut 1970; 11:928-940.
82. Batra A, Stroh T, Siegmund B. Extraluminal factors contributing to inflammatory bowel disease. World J Gastroenterol 2011; 17:572-577.
83. Gore RM, Balthazar EJ, Ghahremani GG, Miller FH. CT features of ulcerative colitis and Crohn's disease. AJR Am J Roentgenol 1996; 167:3-15.
84. Bernstein CN, Greenberg H, Boult I, et al. A prospective comparison study of MRI versus small bowel follow-through in recurrent Crohn's disease. Am J Gastroenterol 2005; 100:2493-2502.
85. Li Y, Zhu W, Gong J, et al. Visceral fat area is associated with a high risk for early postoperative recurrence in Crohn's disease. Colorectal Dis 2015; 17:225-234.
86. Tonelli F, Giudici F, Liscia G. Is lymphatic status related to regression of inflammation in Crohn's disease? World J Gastrointest Surg 2012; 4:228-233.
87. D'Alessio S, Correale C, Tacconi C, et al. VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease. J Clin Invest 2014; 124:3863-3878.